Venitz J, Lücker P W, Niehaus H
Fortschr Med. 1984 Sep 20;102(35):882-4.
The combination of betamethasone and dimetindene maleate (Fenistil Plus) is a new combination of a corticosteroid and an antihistaminic agent. According to the pharmaceutical formula, patients must take three capsules daily, whereby only the morning dose contains betamethasone as well as the antihistaminic. The aim of the study, which was performed on dermatological cases, was to examine the restitution of plasma cortisol concentrations following circadian betamethasone therapy of several days duration, as well as to confirm the clinical effectiveness of the drug combination. The results obtained in the study, carried out in a total of nine Patients suffering from various types of dermatitis, showed that the desired therapeutic effects were achieved. In three patients, plasma cortisol concentrations were found to have returned to normal values within four days after cessation of a ten days treatment. From the above results it may be concluded that permanent adrenocortical suppression is not to be expected in patients treated with betamethasone (0,75 mg) in the morning, for a period of ten days. Furthermore, it may be stated that dimetindene maleate (3 mg/day) in combination with the morning dose of betamethasone proved to be therapeutically effective.
倍他米松与马来酸氯苯那敏(Fenistil Plus)的组合是一种皮质类固醇与抗组胺剂的新组合。根据药物配方,患者必须每天服用三粒胶囊,其中只有早晨的剂量含有倍他米松以及抗组胺剂。这项针对皮肤病病例进行的研究的目的是,研究持续数天的昼夜节律性倍他米松治疗后血浆皮质醇浓度的恢复情况,并确认该药物组合的临床有效性。在总共9名患有各种类型皮炎的患者中进行的研究结果表明,达到了预期的治疗效果。在三名患者中,发现血浆皮质醇浓度在为期十天的治疗停止后四天内恢复到正常值。从上述结果可以得出结论,对于早晨服用倍他米松(0.75毫克)为期十天的患者,预计不会出现永久性肾上腺皮质抑制。此外,可以说,马来酸氯苯那敏(3毫克/天)与早晨剂量的倍他米松联合使用被证明具有治疗效果。